BioHarvest Sciences (NASDAQ:BHST) Posts Earnings Results, Misses Expectations By $0.04 EPS

Key Points

• BioHarvest Sciences reported a loss of ($0.15) earnings per share for the quarter, missing estimates by ($0.04).
• The company's stock increased by 0.7% to reach $8.82, with a market cap of $144.82 million.
• Craig Hallum initiated coverage with a "buy" rating and set a price target of $15.00 for BioHarvest Sciences.

BioHarvest Sciences (NASDAQ:BHST - Get Free Report) posted its earnings results on Monday. The company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.04), Zacks reports. BioHarvest Sciences had a negative net margin of 31.30% and a negative return on equity of 307.04%. BioHarvest Sciences updated its Q3 2025 guidance to EPS.

BioHarvest Sciences Stock Up 0.7%

Shares of NASDAQ:BHST traded up $0.06 during midday trading on Monday, reaching $8.82. The company's stock had a trading volume of 54,638 shares, compared to its average volume of 11,709. BioHarvest Sciences has a 1 year low of $4.66 and a 1 year high of $9.50. The firm has a market cap of $144.82 million, a price-to-earnings ratio of -17.64 and a beta of 0.68. The business has a 50 day moving average price of $7.21 and a 200 day moving average price of $6.36.

Analyst Upgrades and Downgrades

Separately, Craig Hallum initiated coverage on shares of BioHarvest Sciences in a research report on Monday, May 5th. They set a "buy" rating and a $15.00 price target for the company.

BioHarvest Sciences Company Profile

BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.